CpG oligodeoxynucleotide - Wikipedia
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice | npj Vaccines
Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen | Bioconjugate Chemistry
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 | Scientific Reports
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques | Science Advances
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses - ScienceDirect
Spatially Controlled Activation of Toll-like Receptor 9 with DNA-Based Nanomaterials | Nano Letters
Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70 years - ScienceDirect
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70 years - ScienceDirect
SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques | Science Advances
CpG ODN (1826), TLR9 ligand (Class B) | Abeomics | Biomol.de
Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic - Wang - 2022 - Exploration - Wiley Online Library
Publikationen von Prof. Jeltsch | Institut für Biochemie und Technische Biochemie | Universität Stuttgart
Targeting natural killer cells to enhance vaccine responses: Trends in Pharmacological Sciences
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus | SpringerLink
Frontiers | Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21
Development of the CpG Adjuvant 1018: A Case Study | SpringerLink
Development of CpG-Oligodeoxynucleotides for Effective Activation of Rabbit TLR9 Mediated Immune Responses | PLOS ONE
